MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Dr. Hoffman Discusses Sanaria’s Clinical Trials in Africa
An article discussing running clinical trials in Africa features Sanaria's CEO, Dr. Stephen Hoffman.
Sanaria and Collaborators Publish Major Review of PfSPZ Vaccines
The journal Expert Review of Vaccines just published a major, open-access review of the PfSPZ Vaccines co-authored by Sanaria’s staff and 21 collaborators from 25 institutions in the US, Europe, and Africa. The 24,000 word manuscript describes the origins, development, current status and future of Sanaria’s various vaccine platforms, emphasizing the unparalleled safety and protective efficacy of PfSPZ vaccines, innovations that have propelled progress, the critical role played by our collaborators, and the promise of PfSPZ vaccines to reduce the burden of malaria in travelers and residents of malaria-endemic areas across the world.
Company Fishing Trip on the Bay
On August 17th, Sanaria restarted the tradition of the annual fishing trip. Fair winds and blue skies accompanied the team during the morning with a crab feast to top it off. Can't wait till next year!
Sanaria Publishes Results on Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults in the American Journal of Tropical Medicine and Hygiene
On May 9th, the American Journal of Tropical Health and Medicine published on Sanaria's clinical trials' safety results with PfSPZ Vaccine in Equatoguineans.
Sanaria is Runner-Up for Best Logistics Technology and Cold Chain Delivery Award at Vaccine Industry Excellence Awards (World Vaccine Congress)
On April 4th, 2023, Sanaria took second place (highly commended) for Best Logistics Technology and Cold Chain Delivery Award at the Vaccine Industry Excellence at the World Vaccine Congress.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.